Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

Affiliations

• ¹ Quality of Life Office, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland.
• ² International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
• ³ Division of Medical Senology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
• ⁴ Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy/Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
• ⁵ Box Hill and Maroondah Hospitals, Monash University, Victoria, Australia.
• ⁶ Luzerner Kantonsspital, Lucerne, Switzerland.
• ⁷ CHU Liège, Liège University, Liège, Belgium.
• ⁸ Multidisciplinary Breast Center, University Hospitals, KU Leuven, Leuven, Belgium.
• ⁹ Division of Medical Oncology B, CRO-Aviano, Aviano, Italy.
• ¹⁰ Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
• ¹¹ Breast Center St. Gallen, Swiss Group for Clinical Cancer Research and International Breast Cancer Study Group, Bern, Switzerland.
• ¹² The Tweed Hospital, Tweed Heads, NSW & Griffith University Gold Coast, Southport, Australia.
• ¹³ Hospital of Prato-AUSL Toscana Centro, Istituto Toscano Tumori, Prato, Italy.
• ¹⁴ Chilean Cooperative Group for Oncologic Research (GOCCHI), Providencia, Santiago, Chile.
• ¹⁵ CHR Verviers, Verviers, Belgium.
• ¹⁶ CHC Clinique St. Joseph, Liège, Belgium.
• ¹⁷ Bern University Hospital, Inselspital, Bern, Switzerland.
• ¹⁸ Peter MacCallum Cancer Center, University of Melbourne, Melbourne and Breast Cancer Trials Australia & New Zealand, University of Newcastle, Newcastle, Australia.
• ¹⁹ Department of Oncology, Karolinska Institute and University Hospital, Stockholm, Sweden.
• ²⁰ Institute of Oncology of Southern Switzerland, Bellinzona, Geneva University Hospitals, Geneva, Swiss Group for Clinical Cancer Research (SAKK) and International Breast Cancer Study Group, Bern, Switzerland.
• ²¹ Division of Medical Oncology, Ospedale Centrale di Bolzano, Bolzano, Italy.
• ²² Sandton Oncology Centre, Johannesburg, South Africa.
• ²³ International Breast Cancer Study Group Coordinating Center, Bern, Switzerland.
• ²⁴ International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard T.H. Chan School of Public Health and Frontier Science and Technology Research Foundation, Boston, MA, USA.
• ²⁵ International Breast Cancer Study Group and IEO, European Institute of Oncology IRCCS, Milan, Italy.
• ²⁶ International Breast Cancer Study Group and University of Sydney, Sydney, Australia.
• ²⁷ International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
• ²⁸ Quality of Life Office, International Breast Cancer Study Group Coordinating Center and Bern University Hospital, Inselspital, Bern, Switzerland. [email protected].